What is the 13F Pro Quality Score for AORT?

13F Pro ranks ARTIVION, INC. (AORT) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View AORT's current score at https://13fpro.ai/research/AORT (free sign-up required for the full ranking).

Which hedge funds own the most AORT stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of AORT include BlackRock,, FMR, NOMURA ASSET MANAGEMENT INTERNATIONAL. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/AORT as soon as new 13F filings post.

Where does 13F Pro source AORT data?

All ARTIVION, INC. fundamentals and ownership data come directly from SEC EDGAR. ARTIVION, INC. files with the SEC under CIK 784199. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is AORT in?

ARTIVION, INC. (AORT) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is AORT research updated on 13F Pro?

AORT's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

ARTIVION, INC.(AORT)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 784199 AORT stock profile & AI dashboard →

13F Pro Quality Score

48.8/100

Rank #1,537 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

67.2/100

Profitability

56.7/100

Balance Sheet

43.6/100

Earnings Quality

30.0/100

Free Cash Flow

35.0/100

Institutional Flow

86.1/100

Revenue Scale

34.7/100

Dilution Risk

24.4/100

AORT Stock Analysis & AI Quality Score

AI stock analysis and institutional research for ARTIVION, INC. (AORT), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AORT at 48.8/100 on a 32-signal composite quality model, placing it at rank #1,537 of 2,879 stocks — the bottom half of the AI-ranked universe. AORT scores in the top quartile across institutional flow (86.1). Areas of concern include earnings quality (30.0) and revenue scale (34.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 24.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), ARTIVION, INC. reports quarterly revenue of $116.3M, net income of $1.4M, an operating margin of 5.0%. Top institutional holders of AORT by reported 13-F value include BlackRock,, FMR, NOMURA ASSET MANAGEMENT INTERNATIONAL, based on the most recent SEC filings. AORT trades on the NYSE exchange and files with the SEC under CIK 784199. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AORT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ARTIVION, INC. directly from SEC EDGAR. ARTIVION, INC.'s 13F Pro composite quality score has ranged between 8 and 66 since 2022, currently 48.8 — an improving long-term trajectory across 52 quarterly and live scoring snapshots.

Revenue

Q1 2026

$116.3M

Net Income

Q1 2026

$1.4M

Free Cash Flow

Q1 2026

$-6.8M

Operating Margin

Q1 2026

5.0%

ROIC

Q1 2026

0.9%

D/E Ratio

Q1 2026

0.48

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+13.6% YoY

$441.3MFY 2025

FY22 $313.8MFY23 $354.0MFY24 $388.5MFY25 $441.3M

Net Income

+173.1% YoY

$9.8MFY 2025

FY22 $-19.2MFY23 $-30.7MFY24 $-13.4MFY25 $9.8M

Operating Income

-13.2% YoY

$33.7MFY 2025

FY22 $6.2MFY23 $5.7MFY24 $38.9MFY25 $33.7M

EPS (Diluted)

+165.6% YoY

$0.21FY 2025

FY22 $-0.48FY23 $-0.75FY24 $-0.32FY25 $0.21

Total Assets

+12.1% YoY

$884.8MFY 2025

FY22 $762.8MFY23 $792.4MFY24 $789.1MFY25 $884.8M

Total Debt

-31.6% YoY

$215.1MFY 2025

FY22 $309.7MFY23 $308.4MFY24 $314.5MFY25 $215.1M

Op. Cash Flow

+79.3% YoY

$39.9MFY 2025

FY22 $-5.2MFY23 $18.8MFY24 $22.2MFY25 $39.9M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$441.3M +13.6%	$388.5M +9.8%	$354.0M +12.8%	$313.8M +5.0%	$298.8M +18.0%	$253.2M
Net Income	$9.8M +173.1%	$-13.4M +56.5%	$-30.7M -59.9%	$-19.2M -29.4%	$-14.8M +11.1%	$-16.7M
Operating Income	$33.7M -13.2%	$38.9M +577.0%	$5.7M -7.4%	$6.2M -23.6%	$8.1M +232.5%	$2.4M
EPS (Diluted)	$0.21 +165.6%	$-0.32 +57.3%	$-0.75 -56.3%	$-0.48 -26.3%	$-0.38 +13.6%	$-0.44
Total Assets	$884.8M +12.1%	$789.1M -0.4%	$792.4M +3.9%	$762.8M -3.8%	$793.1M +0.5%	$789.4M
Total Debt	$215.1M -31.6%	$314.5M +2.0%	$308.4M -0.4%	$309.7M -0.3%	$310.8M +6.1%	$292.9M
Operating Cash Flow	$39.9M +79.3%	$22.2M +18.1%	$18.8M +465.3%	$-5.2M -99.3%	$-2.6M -120.9%	$12.4M

AI Insight: AORT Financial Trends

ARTIVION achieved revenue acceleration from $97M to $116M with debt reduction of $100M, but operating cash flow turned volatile in latest quarter.

• Revenue accelerated from $97M in Q4 2024 to $116M in Q1 2026, with strongest growth in Q2 2025.

• Total debt decreased from $315M in Q1 2025 to $215M in Q1 2026.

• Equity strengthened from $276M in Q4 2024 to $450M in Q1 2026.

• Company returned to profitability with net income of $7M in Q3 2025 after losses.

⚠ Operating cash flow dropped from $20M in Q4 2025 to $1M in Q1 2026.

⚠ Operating income declined from $13M in Q3 2025 to $6M in Q1 2026.

AI Insight: AORT Ratio Trends

Artivion achieved profitability turnaround with operating margins recovering from 2.2% in Q1 2025 to 8.2% TTM, though momentum slowed in Q1 2026.

• Operating margin surged from 2.2% in Q1 2025 to peak of 11.1% in Q3 2025, settling at 8.2% TTM.

• Company returned to profitability with net margin improving from -0.5% in Q1 2025 to 2.5% TTM.

• Debt-to-equity ratio improved dramatically from 1.36 in Q3 2024 to 0.48 in Q1 2026.

• ROIC expanded from 1.4% in Q1 2025 to 7.7% in Q3 2025 before moderating to 5.6% TTM.

⚠ Operating margin declined sequentially from 9.2% in Q4 2025 to 5.0% in Q1 2026, suggesting potential seasonality.

⚠ ROIC dropped from 7.7% in Q3 2025 to 3.5% in Q1 2026, first quarter-over-quarter decline since turnaround began.

Get alerted when AORT's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for ARTIVION, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of AORT

BlackRock, Inc.
$237.1M6,474,854 sh
FMR LLC
$94.6M2,583,427 sh
NOMURA ASSET MANAGEMENT INTERNATIONAL INC.
$89.9M2,456,146 sh
MORGAN STANLEY
$83.1M2,269,294 sh
VANGUARD CAPITAL MANAGEMENT LLC
$71.5M1,952,008 sh
STATE STREET CORP
$61.6M1,682,273 sh
PERCEPTIVE ADVISORS LLC
$60.0M1,637,290 sh
FRED ALGER MANAGEMENT, LLC
$44.3M1,208,371 sh
Juniper Investment Company, LLC
$43.5M1,189,136 sh
Conestoga Capital Advisors, LLC
$43.0M1,175,410 sh

Fund	Value	Shares
BlackRock, Inc.	$237.1M	6,474,854
FMR LLC	$94.6M	2,583,427
NOMURA ASSET MANAGEMENT INTERNATIONAL INC.	$89.9M	2,456,146
MORGAN STANLEY	$83.1M	2,269,294
VANGUARD CAPITAL MANAGEMENT LLC	$71.5M	1,952,008
STATE STREET CORP	$61.6M	1,682,273
PERCEPTIVE ADVISORS LLC	$60.0M	1,637,290
FRED ALGER MANAGEMENT, LLC	$44.3M	1,208,371
Juniper Investment Company, LLC	$43.5M	1,189,136
Conestoga Capital Advisors, LLC	$43.0M	1,175,410

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put AORT on your watchlist

Track score changes the day ARTIVION, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is AORT a good stock to buy?

13F Pro's AI-powered analysis of ARTIVION, INC. (AORT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AORT are available on the AORT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own AORT?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AORT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ARTIVION, INC.'s investment landscape.